Epsilon substituted lysinol derivatives as HIV-1 protease inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 14, 2010, Pages 4065-4068

  Jones, Kristen L G ^a   Holloway, M Katharine ^a   Su, Hua Poo ^a   Carroll, Steven S ^a   Burlein, Christine ^a   Touch, Sinoeun ^a   DiStefano, Daniel J ^a   Sanchez, Rosa I ^a   Williams, Theresa M ^a   Vacca, Joseph P ^a   Coburn, Craig A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

HIV 1 protease inhibitor; Lysinol sulfonamide

Indexed keywords

AMINO ACID DERIVATIVE; ANTIVIRUS AGENT; EPSILON; LYSINOL SULFONAMIDE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONFORMATION; CRYSTAL STRUCTURE; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN;

HIV PROTEASE INHIBITORS; LYSINE; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77953873671     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.05.082     Document Type: Article

References (19)

1. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., and Holmberg S.D. N. Engl. J. Med. 338 (1998) 853
2. Richman D.D., Morton S.C., Wrin T., Hellmann N., Berry S., Shapiro M.F., and Bozzette S.A. AIDS 18 (2004) 1393
3. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimback J.C., Dixon R.A., Scolnick E.M., and Sigal I.S. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 4686
4. Stranix B.R., Lavallée J.-F., Sévigny G., Yelle J., Perron V., LeBerre N., Herbart D., and Wu J.J. Bioorg. Med. Chem. Lett. 16 (2006) 3459
5. Dandache S., Coburn C.A., Oliveira M., Allison T.J., Holloway M.K., Wu J.J., Stranix B.R., Panchal C., Wainberg M.A., and Vacca J.P. J. Med. Virol. 80 (2008) 2053
6. Chellappan S., Kairys V., Fernandes M.X., Schiffer C., and Gilson M.K. Proteins: Struct. Funct. Bioinformatics 68 (2007) 561
7. Halgren T.A. J. Comput. Chem. 17 (1996) 490
8. Halgren T.A. J. Comput. Chem. 17 (1996) 520
9. Halgren T.A. J. Comput. Chem. 17 (1996) 553
10. Halgren T.A., and Nachbar R.B. J. Comput. Chem. 17 (1996) 587
11. Halgren T.A. J. Comput. Chem. 17 (1996) 616
12. Wang R., Lu Y., Fang X., and Wang S. J. Chem. Inf. Comput. Sci. 44 (2004) 2114
13. For synthetic procedures, see: Coburn, C. A.; Vacca, J. P.; Rajapakse, H. A.; Jones, K. L. G.; Nantermet, P.; Barrow, J. C.; Moore, K. P.; Sharik, S. S.; Theberge, C.; Walji, A. M. WO 2009042093.
14. R = iPr was prepared from 1-iodo-2-methylpropane and catalytic base, tetramethylguanidine, see:. Kornblum N., and Ungnade H.E. Org. Synth. 4 (1963) 724 1958, 38, 75
15. 2Me, 1 N NaOH, 77%, followed by N-hydroxysuccinimide, DCC, dioxane, 0 °C.
16. 95) are defined as those which inhibited by 95% the spread of HIV-1 infection in susceptible cell culture. MT-4 human T-lymphoid cells were maintained in RPMI 1640 medium containing 10% heat inactivated fetal bovine serum. Cells were infected en masse at low multiplicity (0.01) using HIV-1 strain IIIb and were incubated for 24 h. At this time, cells were washed and distributed into 96 well microtiter dishes. Cells were resuspended in media containing 50% normal human serum (Lonza). Serial twofold dilutions of inhibitor were added to the wells and the cultures were maintained for three additional days. Virus spread was assessed by HIV-1 p24 core antigen ELISA. Control cultures in the absence of inhibitor were fully infected at 4 days
17. Version 8.5.207, Schrödinger, LLC, New York, NY, www.schrodinger.com.
18. Boltzmann population analysis script (Revision 1.16) downloaded from www.schrodinger.com.
19. Phenotypic drug susceptibility assay performed by Monogram Biosciences, see:. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W., Tian H., Smith D., Winslow G.A., Capon D.J., and Whitcomb J.M. Antimicrob. Agents Chemother. 44 (2000) 920